These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 25988858

  • 1. Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease.
    Lieberman LA, Mizui M, Nalbandian A, Bossé R, Crispín JC, Tsokos GC.
    Clin Immunol; 2015 Oct; 160(2):286-91. PubMed ID: 25988858
    [Abstract] [Full Text] [Related]

  • 2. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.
    Shi Y, Yao W, Sun L, Li G, Liu H, Ding P, Hu W, Xu H.
    BMC Nephrol; 2019 Nov 21; 20(1):424. PubMed ID: 31752725
    [Abstract] [Full Text] [Related]

  • 3. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, Seccareccia E, Bosanac T, Khalil S, Harcken C, Webb D, Nabozny G, Fine JS, Souza D, Klein E, Herlitz L, Ramanujam M, Putterman C.
    Clin Immunol; 2018 Dec 21; 197():205-218. PubMed ID: 30339790
    [Abstract] [Full Text] [Related]

  • 4. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
    Keil A, Hall SR, Körner M, Herrmann M, Schmid RA, Frese S.
    Arthritis Res Ther; 2016 Oct 22; 18(1):243. PubMed ID: 27770825
    [Abstract] [Full Text] [Related]

  • 5. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice.
    Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S.
    J Immunol; 2008 Jan 15; 180(2):1231-8. PubMed ID: 18178863
    [Abstract] [Full Text] [Related]

  • 6. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.
    Chalmers SA, Wen J, Shum J, Doerner J, Herlitz L, Putterman C.
    Clin Immunol; 2017 Dec 15; 185():100-108. PubMed ID: 27570219
    [Abstract] [Full Text] [Related]

  • 7. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.
    Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS.
    J Immunol; 2000 Jan 15; 164(2):786-94. PubMed ID: 10623824
    [Abstract] [Full Text] [Related]

  • 8. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
    Kikawada E, Lenda DM, Kelley VR.
    J Immunol; 2003 Apr 01; 170(7):3915-25. PubMed ID: 12646661
    [Abstract] [Full Text] [Related]

  • 9. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
    Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS.
    Kidney Int; 2004 Jan 01; 65(1):129-38. PubMed ID: 14675043
    [Abstract] [Full Text] [Related]

  • 10. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
    Yao L, Chen HP, Ma Q.
    Immunol Lett; 2014 Sep 01; 161(1):76-80. PubMed ID: 24837470
    [Abstract] [Full Text] [Related]

  • 11. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
    Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S.
    Arthritis Rheum; 2011 Apr 01; 63(4):1076-85. PubMed ID: 21452327
    [Abstract] [Full Text] [Related]

  • 12. Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus.
    Liang B, Kashgarian MJ, Sharpe AH, Mamula MJ.
    J Immunol; 2000 Sep 15; 165(6):3436-43. PubMed ID: 10975864
    [Abstract] [Full Text] [Related]

  • 13. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

  • 14. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.
    J Rheumatol; 2010 Jan 15; 37(1):60-70. PubMed ID: 19955044
    [Abstract] [Full Text] [Related]

  • 15. Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in Faslpr Mice.
    Zhou Y, Chen H, Liu L, Yu X, Sukhova GK, Yang M, Kyttaris VC, Stillman IE, Gelb B, Libby P, Tsokos GC, Shi GP.
    J Immunol; 2017 Mar 01; 198(5):1846-1854. PubMed ID: 28093526
    [Abstract] [Full Text] [Related]

  • 16. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K, Tiede A, Jacob U, Schmidt RE, Witte T.
    Ann Rheum Dis; 2008 Feb 01; 67(2):154-61. PubMed ID: 17557887
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice.
    Grossman TR, Hettrick LA, Johnson RB, Hung G, Peralta R, Watt A, Henry SP, Adamson P, Monia BP, McCaleb ML.
    Immunobiology; 2016 Jun 01; 221(6):701-8. PubMed ID: 26307001
    [Abstract] [Full Text] [Related]

  • 18. Essential Roles for Mannose-Binding Lectin-Associated Serine Protease-1/3 in the Development of Lupus-Like Glomerulonephritis in MRL/lpr Mice.
    Machida T, Sakamoto N, Ishida Y, Takahashi M, Fujita T, Sekine H.
    Front Immunol; 2018 Jun 01; 9():1191. PubMed ID: 29892304
    [Abstract] [Full Text] [Related]

  • 19. Siglec-G deficiency leads to more severe collagen-induced arthritis and earlier onset of lupus-like symptoms in MRL/lpr mice.
    Bökers S, Urbat A, Daniel C, Amann K, Smith KG, Espéli M, Nitschke L.
    J Immunol; 2014 Apr 01; 192(7):2994-3002. PubMed ID: 24600033
    [Abstract] [Full Text] [Related]

  • 20. Glomerular Injury Is Exacerbated in Lupus-Prone MRL/lpr Mice Treated with a Protease-Activated Receptor 2 Antagonist.
    Itto R, Oe Y, Imaruoka K, Sato E, Sekimoto A, Yamakage S, Kumakura S, Sato H, Ito S, Takahashi N.
    Tohoku J Exp Med; 2019 Oct 01; 249(2):127-133. PubMed ID: 31666446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.